1-10 of 10
Ian Collins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LBA004: Identification of GSPT1-directed molecular glue degrader (MGD) for the treatment of Myc-driven breast cancer

Gerald Gavory, Bernhard Fasching, Debora Bonenfant, Amine Sadok, Ambika Singh, Martin Schillo, Vittoria Massafra, Anne-Cecile d’Alessandro, John Castle, Mahmoud Ghandi, Agustin Chicas, Frederic Delobel, Alexander Flohr, Giorgio Ottaviani, Thomas Ryckmans, Anne-Laure Laine, Oliv Eidam, Hannah Wang, Ilona Bernett, Laura Chan, Chiara Gorrini, Theo Roumiliotis, Jyoti Choudhary, Yann-Vai LeBihan, Marc Cabry, Mark Stubbs, Rosemary Burke, Rob Van Montfort, John Caldwell, Rajesh Chopra, Ian Collins, Silvia Buonamici
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): LBA004.
https://doi.org/10.1158/1535-7163.TARG-21-LBA004
Published: 01 December 2021
View article titled, Abstract LBA004: Identification of GSPT1-directed molecular glue degrader (MGD) for the treatment of Myc-driven breast cancer
Journal Articles

Abstract A024: Probe Miner: objective, quantitative, data-driven assessment of chemical probes for target validation

Albert A. Antolin, Joe E. Tym, Angeliki Komianou, Ian Collins, Paul Workman, Bissan Al-Lazikani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A024.
https://doi.org/10.1158/1535-7163.TARG-17-A024
Published: 01 January 2018
View article titled, Abstract A024: Probe Miner: objective, quantitative, data-driven assessment of chemical probes for target validation
Journal Articles

Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture.

Florence I. Raynaud, Angela Hayes, Yasmin J. Asad, Louise Johnson, Alan T. Henley, John J. Caldwell, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B190.
https://doi.org/10.1158/1535-7163.TARG-11-B190
Published: 12 November 2011
View article titled, Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture.
Journal Articles

Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.

Michael I. Walton, Paul E. Eve, Angela Hayes, Melanie R. Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth L. Smith, Kathy J. Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John C. Reader, Louis Chesler, Florence I. Raynaud, Suzanne E. Eccles, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A228.
https://doi.org/10.1158/1535-7163.TARG-11-A228
Published: 12 November 2011
View article titled, Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.
Journal Articles

Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.

Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung, Jane Scanlon, Michael Lainchbury, Nelly Piton, Martin Fisher, Michael Cherry, Kathy Boxall, Michael I. Walton, Isaac M. Westwood, Angela Hayes, Paul Eve, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Rob L. M. van Montfort, David H. Williams, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett, John C. Reader, Ian Collins
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A235.
https://doi.org/10.1158/1535-7163.TARG-11-A235
Published: 12 November 2011
View article titled, Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.
Journal Articles

Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter, Melanie Valenti, Alexis de Haven Brandon, Paul D. Eve, Ruth Ruddle, Simon P. Heaton, Alan Henley, Lisa Pickard, Gowri Vijayaraghavan, John J. Caldwell, Neil T. Thompson, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 360–371.
https://doi.org/10.1158/1535-7163.MCT-10-0760
Published: 08 February 2011
View article titled, Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Open the PDF for Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 in another window
Includes: Supplementary data
Journal Articles

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis De Haven Brandon, Gary Box, Kathy J. Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, David H. Williams, John C. Reader, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 89–100.
https://doi.org/10.1158/1535-7163.MCT-09-0938
Published: 12 January 2010
View article titled, The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
Open the PDF for The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 in another window
Includes: Supplementary data
Journal Articles

Abstract C208: CCT129254 (AT11854) is a well tolerated, orally bioavailable inhibitor of AKT/PKB with pharmacodynamic and antitumor activity in a range of xenograft models

Barry R. Davies, Philippa Dudley, Sabina Cosulich, Richard Luke, Neil Thompson, Ian Collins, Tatiana McHardy, Michelle Garrett, Donald Ogilvie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C208.
https://doi.org/10.1158/1535-7163.TARG-09-C208
Published: 10 December 2009
View article titled, Abstract C208: CCT129254 (AT11854) is a well tolerated, orally bioavailable inhibitor of AKT/PKB with pharmacodynamic and antitumor activity in a range of xenograft models
Journal Articles

AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation.

John Lyons, Kyla Grimshaw, Steven Woodhead, Ruth Feltell, Matthias Reule, Tomko Smyth, Lisa Seavers, Isobelle Harada, Jacqueline Higgins, Donna Smith, Lynsey Fazal, Paul Workman, Ian Collins, Michelle Garrett, Neil Thompson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B251.
Published: 01 November 2007
View article titled, AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both <em>in vitro</em> and <em>in vivo</em> models exhibiting AKT pathway deregulation.
Journal Articles

A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation

Anthea Hardcastle, Peter Tomlin, Clair Norris, Juliet Richards, Matthew Cordwell, Katherine Boxall, Martin Rowlands, Keith Jones, Ian Collins, Edward McDonald, Paul Workman, Wynne Aherne
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (3): 1112–1122.
https://doi.org/10.1158/1535-7163.MCT-06-0496
Published: 15 March 2007
View article titled, A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation
Open the PDF for A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation in another window